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Abstract
Focal point-by-point radiofrequency catheter ablation has shown considerable success in the 
treatment of paroxysmal atrial fibrillation. However, it is not without limitations. Recent 
clinical and preclinical studies have demonstrated that cryothermal ablation using a balloon 
catheter (Artic Front©, Medtronic CryoCath LP) provides an effective alternative strategy to 
treating atrial fibrillation. The objective of this article is to review efficacy and safety data 
surrounding cryoballoon ablation for paroxysmal and persistent atrial fibrillation. In addition, 
a practical step-by-step approach to cryoballoon ablation is presented, while highlighting 
relevant literature regarding: 1) the rationale for adjunctive imaging, 2) selection of an 
appropriate   cryoballoon   size,   3)   predictors   of   efficacy,   4)   advanced   trouble-shooting 
techniques, and 5) strategies to reduce procedural complications, such as phrenic nerve palsy. 
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Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia.  It accounts for the 
majority of arrhythmia-related emergency room visits and hospital admissions,[1-3] and is 
associated with reductions in quality of life, functional status, cardiac performance, and overall 
survival.[1] Catheter ablation, which is centered on electrical isolation of triggering foci within 
the pulmonary veins (PV) through circumferential lesions around PV ostia, has been shown to 
result in sustained improvements in quality of life, decreased hospitalizations and, potentially, 
improved survival.[4-6]                                                                                                             
Radiofrequency   (RF)   catheter   ablation   has   shown   considerable   success   in   treating 
symptomatic AF, particularly in comparison to anti-arrhythmic drugs [7,8]. Unfortunately, 
major complications including thromboembolism, cardiac perforation, and injury to adjacent 
structures are not infrequently observed [2,3,7,9,10]. Further, the procedure is complex, time-
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consuming and highly dependent on operator competency given the inherent difficulties 
associated with creating contiguous curvilinear lesions with a technique originally developed 
for focal ablation. As such, considerable effort has been directed towards developing 
technologies specifically for PV isolation (PVI) as a means to achieve safer and more effective 
PVI that is less reliant on operator dexterity. Recently clinical and preclinical studies have 
demonstrated that cryothermal ablation using a balloon catheter (Artic Front©, Medtronic 
CryoCath LP, Kirkland, Canada) is an effective alternative treatment for AF.               
Efficacy of Cryoballoon Ablation                                                                         
To  date  over  20,000  cryoballoon-based  PV  ablation  procedures  have  been  performed 
worldwide. In a recent systematic review and meta-analysis, we reported the cumulative early 
experience with cryoballoon-based ablation (CBA).[11] CBA resulted in a high procedural 
success rate (>98% of patients achieving complete PVI) and 1-year freedom from recurrent 
AF (single cryoballoon procedure off anti-arrhythmic drugs 1-year success of 60%; 73% if a 
3-month blacking period was included) [11,12]. In comparison, the longer-term freedom from 
recurrent AF after RF catheter ablation has been reported to be 50% to 64% after a mean 
follow-up of 14 months in the meta-analysis by Calkins et al. and 39.8±5.1% at 1 year in the 
prospective long-term cohort study by Weerasooriya et al.[7,13] Thus, the early experience 
suggests that cryoballoon ablation is efficacious for the maintenance of sinus rhythm at 1 year 
in patients with paroxysmal AF.                                                                           
When compared to other rhythm control strategies, CBA has performed favourably. (See 
Table 1) The first randomized trial comparing AAD therapy and cryoballoon ablation, the 
Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP-AF) trial, enrolled 245 patients 
with paroxysmal AF and randomized them (2:1) to cryoballoon-based PV isolation (n=163) or 
to AAD therapy (n=82).[14] The mean age of participants was 57 years, and those enrolled 
had already failed an average of 1.2 AADs. Balloon-only PVI was realised in 90.8% of 
participants, with an overall procedural success (≥3 PVs isolated) of 98.2% when focal 
cryoablation was added. Nineteen percent of patients required a repeat procedure within the 3-
month blanking period. At 12 months of follow-up, 69.9% of the cryoballoon group (114/163) 
vs. 7.3% of the AAD group (6/82) were free of recurrent AF (p<0.001). Moreover, there was a 
statistically significant improvement in symptoms and quality of life in the cryoablation group. 
For all quality-of-life metrics, the improvement was greater in the cryoballoon group when 
compared to the AAD group.
Likewise, in comparison to other contemporary AF ablation technologies, CBA has performed 
favourably. In general, CBA is associated with procedure and fluoroscopy times that are 
somewhat longer than duty-cycled multi-electrode RF ablation but shorter than conventional 
RF ablation.[15-19] Despite these procedural differences, efficacy outcomes at all of time 
points sampled did not differ between CBA and conventional, magnetic guided, and duty-
cycled multi-electrode RF ablation. [15-19,20]                                                                   
Safety of Cryoballoon Ablation                                                                                     
Major complications have been reported in approximately 5-6% of patients undergoing RF 
ablation   for   AF   [7,9,10].   The   rate   of   acute   procedural   complications   reported   with 
cryoballoon-based ablation (CBA) is relatively low (<3-5%) and compares favourably with 
irrigated RF and duty-cycled multi-electrode RF ablation [7,9,10,21]. With CBA, the reported 
rate of peri-procedural stroke or transient ischemic attack (TIA) is 0.3%, cardiac tamponade 
0.6%, and groin complications 1.8%. In comparison, corresponding reported complication 
rates with RF ablation are 0.3-0.9% for stroke or TIA, 0.8-1.3% for cardiac tamponade, and 1-
1.5% for groin complications.[11] Longer-term complications such as symptomatic PV 
stenosis and esophageal injury occurred infrequently with CBA (0.17% for symptomatic PV 
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stenosis and a 0% incidence of atrial-oesophageal fistula).[11] Given the inclusion of patients 
early in the operators' learning curves, it is possible that the rate of complications with CBA 
will decrease further as operators gain experience.
Table 1: Studies Comparing Cryoballoon-Based Ablation To Other Rhythm Control Methods
AAD - Antiarrhythmic drugs; Magnet - Magnetic-assisted RF; MESH - Mesh Ablator catheter; NR - Not 
reported; NS - Not significant; PVAC - duty-cycled multi-electrode ablation; RF - convention radiofrequency 
catheter ablation
While the global complication rate with CBA appears comparable to conventional RF 
ablation, three complications merit further discussion. Initially described in the early animal 
studies by Sarabanda et al., phrenic nerve palsy (PNP) has proven to be the most frequently 
observed complication with CBA, occurring in approximately 6% of clinical procedures 
(range 3-11%) [11,22,23]. While PNP can be observed after AF ablation regardless of the 
energy source, it occurs disproportionately more frequently with balloon-based ablation 
technologies when compared to conventional RF ablation [7,9,10]. Fortunately, despite PNP 
being a relatively common occurrence, the majority of cases are transient with <0.4% of PNPs 
persisting greater than one year.[11] However, while persistent PNP is rare, the incidence 
appears to be approximately twice that reported with conventional RF ablation (0.17%).[9]
The most commonly employed preventative measure is the use of continuous abdominal 
palpation during phrenic nerve pacing from a catheter placed in the superior vena cava cranial 
to the right-sided PVs. However, despite early interruption of ablation with the perceived onset 
of less vigorous diaphragmatic contractions, PNP continues to be observed. As such, efforts 
have been directed towards determining a more effective method for detecting early changes to 
the phrenic nerve. One such approach involving the use of diaphragmatic electromyography 
(EMG) has  recently  been published.[22] During phrenic  nerve pacing, a reproducible 
supramaximal diaphragmatic compound motor action potential (CMAP) can be reliably 
recorded, providing valuable information about phrenic nerve function. In a recent animal 
study, it was demonstrated that a 30% reduction in CMAP amplitude reliably predicted 
impending hemidiaphragmatic paralysis (presaging diaphragmatic paralysis by abdominal 
palpation by 31 ± 23 seconds).[22]  The first clinical application of this technique has also 
been   reported.[24]                                                                        
The second complication that warrants a more in depth discussion is that of PV stenosis, as its 
incidence with CBA is somewhat controversial. Prior to the recent STOP-AF trial, PV stenosis 
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was thought to be non-existent after CBA. While multiple studies employing the use of 
systematic screening reported no PV stenosis (0/550 patients), the landmark STOP-AF trial 
noted a 3.07% (7/228 patients) incidence of radiographic PV stenosis [14,25-32]. It is most 
likely that this incongruity reflects differences in criteria to define significant PV stenosis. In 
the AF ablation literature, PV stenosis is most commonly defined on the basis of diameter 
measurements (typically as a reduction in PV diameter >70%).[8] In contrast, STOP-AF 
defined PV stenosis as a >75% reduction in cross-sectional area from baseline, which 
corresponds to a 50% reduction in PV diameter.[14] As such, this more liberal definition may 
represent a relative overestimate of the rate of PV stenosis and limits direct comparisons to 
other studies. Even so, when the results of STOP-AF were combined with other studies 
employing systematic screening with non-invasive imaging, the incidence of radiographic PV 
stenosis was 0.90% (7/773 procedures), which is approximately half the rate observed in a 
large meta-analysis of conventional AF ablation with RF [7,25-32]. Reassuringly, the rate of 
symptomatic PV stenosis or PV stenosis requiring intervention was low (0.17%) and 
comparable to that observed with RF (0.1-0.3%) [7,9,10].                                 
The   final   complication   that   warrants   a   detailed   discussion   is   that   of   systemic 
thromboembolism. Cerebral ischemic events are a recognized complication of left atrial 
catheter ablation. In the recent systematic review of CBA, the incidence of thromboembolic 
complications,   including   peri-procedural   stroke   or   TIA,   was   0.32%,   which   compares 
favourably to conventional RF ablation (0.3-0.94%) [7,9,10].                                
Recognising that not all embolic cerebral events lead to clinical symptomatology, a series of 
studies recently examined signs of subclinical disease in an attempt to further delineate the risk 
of systemic thromboembolism after AF ablation. Sauren et al. examined the incidence of 
cerebral microembolic signals (MES) as a surrogate for neurological impairment and stroke in 
30   patients   undergoing   percutaneous   endocardial   AF   ablation:   10   patients   undergoing 
segmental PVI using a 4-mm conventional (non-irrigated) RF ablation catheter, 10 patients 
undergoing segmental PVI using a 4-mm irrigated-tip RF catheter, and 10 patients undergoing 
circumferential   PVI   with   CBA.[33]   In   this   small   study,   the   authors   demonstrated   a 
significantly lower incidence of MES in the middle cerebral arteries with CBA and irrigated 
RF catheters when compared to conventional non-irrigated RF (935±463 and 1,404±981 
versus 3,908±2816 total MES respectively). Similarly, two recent studies comprising a total of 
182 patients compared the incidence of silent cerebral ischemic lesions after PV isolation with 
duty-cycled multi-electrode ablation, conventional irrigated-tip RF ablation, and CBA. In both 
studies the incidence of new silent cerebral ischemic lesions, which have been associated with 
neurocognitive decline, was found to be significantly higher with multi-electrode ablation 
(37.5-38.9%) when compared to irrigated RF (7.4-8.3%) or CBA (4.3-5.6; overall P=0.008 for 
Siklody et al, and overall P=0.002 for Gaita et al.) [34,35].                                 
How to Perform Cryoballoon Ablation                                                                 
Patient   Selection                                                                    
In current practice, cryoballoon-based AF ablation is reserved for patients undergoing their 
first left atrial ablation for drug-refractory symptomatic paroxysmal AF or early persistent AF. 
While over 20,000 cryoballoon procedures have been performed worldwide, the vast majority 
of patients undergoing the procedure have had paroxysmal AF.                          
Left   Atrial   Access                                                                                          
The ablation procedure is commenced  by gaining left atrial access using a modified 
Brockenbrough technique and standard transseptal sheath [typically SL0, SL1 or SR0]. It is 
important to ensure that transseptal puncture used for cryoballoon ablation is located in a low 
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anterior position within the membranous septum. Punctures in a more posterior position or 
within the muscular septum limit the manoeuvrability of the cryoballoon-FlexCath apparatus, 
potentially leading to technical challenges.                                                                       
Early in our experience, we evaluated PV potentials (PVPs) though the introduction of a 
conventional diagnostic spiral catheter through a second more posteriorly located transseptal 
puncture. Recently, we modified our technique to perform only a single transseptal puncture. 
Evaluation of PVPs is now performed through the use of a small calibre 15 or 20-mm diameter 
circular mapping catheter introduced into the central lumen of the cryoballoon catheter 
(Achieve catheter; Medtronic; Minneapolis, MN). The Achieve catheter serves the dual 
purpose of acting as guide wire, as well as providing real-time verification of PVI during the 
freezing cycle, a period during which the placement of a conventional diagnostic spiral 
catheter is precluded by cryoballoon-induced PV occlusion. A third possible approach, one 
that we do not advocate due to additional risks that we consider unnecessary, is to perform a 
single transseptal puncture and serially exchange the cryoballoon catheter for a conventional 
spiral catheter. It should be noted that none of these approaches have been demonstrated to 
positively or negatively effect long-term outcomes and, as such, the decision to perform 1 or 2 
transseptal punctures is based on physician preference.                                   
Once left atrial access is obtained, a heparin bolus and subsequent infusion are commenced to 
target activated clotting times of 300 seconds. At the operator's discretion, selective or non-
selective pulmonary venography is performed in the antero-posterior projection using a pigtail, 
multipurpose (MP), or National Institute of Health (NIH) catheter to delineate PV anatomy. 
Thereafter, a 300-cm 0.035-inch J-tipped guide wire is positioned in the left superior PV and 
the standard transseptal sheath is exchanged over the wire for a 12-Fr deflectable delivery 
sheath (15-Fr outer diameter; FlexCath, Medtronic, Minneapolis, MN).                                    
The Use Of Adjunctive Imaging                                                                                           
The use of adjunctive pre-procedural and intra-procedural imaging has remained a matter of 
physician preference. Although contentious, there are some reports suggesting that atypical PV 
anatomy such as common PV ostia may influence longer-term efficacy [18,36]. Kubala et al. 
evaluated PV anatomic patterns in 118 consecutive patients with drug refractory paroxysmal 
(72%) or persistent (28%) AF [36]. The authors demonstrated that the presence of a normal 
PV pattern is associated with fewer recurrences of AF at 13 months of follow-up, when 
compared to patients with left common ostia (67% vs. 50%, P = 0.02). The authors postulated 
that this difference might represent increased difficulty in obtaining circumferential lesions in 
the common ostia due to larger ostial diameters, an atypical ostial circumferential geometry, 
and/or a larger border zone between PV tissue and atrial myocardium in comparison to non-
common PV ostia. In contrast, Sorgente et al. found no difference in the degree of PV 
occlusion or longer-term efficacy endpoints between patients with a left common ostium and 
those with normal branching of left PVs [18]. Given the conflicting reports regarding the 
influence of atypical PV anatomy on longer-term efficacy outcomes, we do not consider the 
presence of common PV ostia to contraindicate CBA [18].                                     
As such, in our opinion, the main benefit of adjunctive imaging lies in the assessment PV 
diameter and selection of the appropriately sized cryoballoon [26,37]. We rely on the 
combination of pre-procedural cardiac magnetic resonance imaging and intra-procedural 
pulmonary venography and/or intracardiac echocardiography to define pulmonary venous 
anatomy and calibre. While venography is widely available and easy to perform, the use of 
intraprocedural intracardiac or transesophageal echocardiography provides a supplemental 
assessment of PV occlusion through the use of colour flow doppler (CFD) imaging. Total 
occlusion of the PV, as confirmed by CFD, successfully predicts PVI with a positive 
predictive value of 93-98%. Conversely, a negative predictive value for successful PVI of 92-
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100% was found in cases of persistent leak [30,38]. While it has been reported that procedure 
and fluoroscopy times can be reduced through the use of intracardiac echocardiography, the 
use of pre- or intraprocedural imaging has not been shown to directly affect longer-term 
efficacy. As such, the use of pre-procedural or intraprocedural imaging are largely based upon 
cost, physician preference, and regional patterns of practice.                                   
Choosing a Cryoballoon: 23 mm vs. 28 mm                                                    
The current generation cryoballoon catheter is available in two sizes, i.e., with 23 or 28 mm 
diameter balloons. Some operators prefer exclusive use of the larger 28 mm cryoballoon, 
whereas others have adopted a "toolbox" approach, with selective use of both the 23 mm and 
28 mm cryoballoon. Advocates for the single large cryoballoon approach highlight the high 
rate of PNP retrospectively observed with the 23 mm balloon, while proponents of the toolbox 
approach emphasize the potential for increased long-term efficacy [25,39].                      
The premise underlying the argument for exclusive use of the larger 28 mm cryoballoon 
relates to the relative cryoballoon to PV (CB-PV) diameter and how that relationship 
influences the position of the resultant lesion. Early attempts to explain the excess incidence of 
PNP in association with 23 mm cryoballoon ablation (12.4% vs. 3.5% incidence with the 28 
mm cryoballoon) postulated that the deployment of relatively undersized balloons deep inside 
the PV could result in an increased risk of PNP [40]. In addition to minimising the physical 
distance between the cryoballoon and phrenic nerve, CBA at a relatively more distal site 
within the RSPV results in a local environment more conducive to enhanced "cold" transfer to 
deeper tissue due to less convective heating of the balloon by atrial blood flow. As such, the 
"freeze" affected by a more distal cryoballoon position can be expected to result in deeper 
penetration of cryoenergy.  Consequently, some operators have suggested that the incidence of 
PNP can be minimized through the exclusive use of the 28-mm balloon [15,25,40]. However, 
re-examination of the evidence has cast doubt on the validity of this assertion. While the 
observed early excess of PNP with the 23 mm CBA cannot be denied, it is important to note 
that the exclusive use of larger balloons has not entirely eliminated this complication. "Over-
sizing" the balloon within the RSPV may result in: 1) mechanical distortion of the RSPV 
orifice with an even greater shortening of the relative distance between the cryoballoon and 
phrenic nerve, and 2) physical impingement of the phrenic nerve with resultant palsy [23]. 
It may be reasonably argued that the critical factor in preventing PNP is the avoidance of distal 
CBA by insuring that the diameter of the cryoballoon exceeds the diameter of the vein. While 
Chun et al recommended a critical PV to cryoballoon ratio of 0.93 when using the 28 mm 
cryoballoon for septal PVs, the authors did not derive a comparable ratio for left-sided veins 
nor for the 23 mm balloon [40]. In this regard, recent studies by Vogt et al. and Nadji et al. 
have shown that the 23 mm cryoballoon can be safely used to treat PVs smaller than 18 to 20 
mm, respectively. Taken together, it appears that a CB-PV ratio of 0.9 may be appropriate for 
the 28 mm cryoballoon and that a CB-PV ratio of 0.8-0.85 may be preferable for the 23 mm 
balloon   [37,39].                                                                                             
Our approach is to perform pre- and/or intra-procedural imaging to guide cryoballoon catheter 
selection. In general, when the PV diameter is less than 20 mm, we favour use of a 23 mm 
balloon.   With larger PV diameters or common ostia, we resort to the use of a 28 mm 
cryoballoon.
 
Balloon Preparation and Ablation                                                                                         
Once the appropriate balloon is selected, the central lumen is flushed with saline prior to 
insertion of an extra support, 0.035-inch J-tipped guide wire (or Achieve catheter) via a 
Tuohy-Borst adaptor. Thereafter, the cryoballoon catheter is advanced through the FlexCath 
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into the left atrium where the guidewire (or Achieve catheter) is advanced into the targeted 
PV. We begin by targeting left-sided veins, working superiorly to inferiorly. Once the targeted 
vein is engaged with the guidewire, the cryoballoon is inflated in the body of the left atrium 
and advanced over the wire to the PV ostium. It is important to first inflate the balloon in the 
left atrium rather than inside the PV in order to avoid distal inflation, which potentially 
increases   the   risk   of   PV   damage,   phrenic   nerve   injury,   and   pulmonary   necrosis.  
PV Occlusion and Lasting Isolation                                                                             
To achieve lasting PVI, circumferential tissue contact must be attained. Failure to fully 
occlude the targeted PV during CBA will result in convective heating by intervening blood, 
which reduces the efficiency of freezing and the durability of the lesion.                     
Typically, the assessment of balloon occlusion is performed through the injection of 50% 
diluted contrast through the cryoballoon catheter's central lumen. (See Figure 1) In addition to 
providing confirmation of circumferential contact, which can be graded on a semi-quantitative 
scale from 1 (negligible occlusion with immediate rapid outflow from the PV) to 4 (total 
occlusion with complete contrast retention), contrast injection also provides information on the 
exact position of the inflated balloon in relation to the PV–LA junction. Alternative methods 
for assessing the adequacy of balloon occlusion include color flow doppler echocardiography 
(i.e. the absence of proximal flow on either transesophageal or intracardiac echo) as well 
pulmonary venous pressure assessment (i.e. the transition from a left atrial to pulmonary 
arterial pressure waveforms). The latter two methods allow for assessment of dynamic 
occlusion during cryoablation (i.e. with advanced manoeuvres such as the "pull down" 
technique), a period where confirmation of occlusion is not possible with contrast injection 
due to freezing of the central lumen of the cryoballoon catheter.
Figure 1: Cryoballoon Ablation of the Left Superior PV. Panel A. Cryoballoon (CB) ablation using a standard 
0.035-inch J-tipped guidewire. A grade three occlusion is demonstrated with the persistence of a small inferior 
leak (Arrow). Axial catheter rotation and slight relaxation of the forward pressure resulted in complete occlusion 
(not depicted). Of note a circular mapping catheter (CMC) is pictured on the left side of the image in the right 
superior PV. Panel B. Cryoballoon ablation the Achieve mapping catheter. Complete (grade 4) occlusion is 
demonstrated. In both images a coronary sinus (CS) catheter is pictured.                                                       
While every effort should be made to achieve optimal cryoballoon occlusion prior to ablation, 
it should be noted that a small degree of localized leak or delayed emptying of contrast (grade 
3 occlusion) may be acceptable, since the onset of cryoablation is associated with balloon 
expansion, which may improve the seal.                                                                     
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Management of Inadequate Seal                                                                                   
While left-sided veins and the right superior vein may usually be directly approached, 
variability   in   ostial   geometry   and   orientation   can   impede   adequate   circumferential 
cryoballoon-PV contact. In this case, the simplest and most effective manoeuvre is the 
combination of axial catheter rotation, catheter flexion, and/or repositioning of the guidewire 
within a different distal PV branch in order to reorient the balloon's axis. It is important to note 
that the current generation cryoballoon catheter relies on four equatorial anteriorly directed 
refrigerant jets to produce the lowest ablation temperatures in a large circular zone from the 
balloon equator and extending a few mm towards its distal part. As such, should optimal 
occlusion only occur when the catheter shaft is misaligned compared to the axis of the PV, 
step-wise ablation should be performed from two different branches of the same vein to ensure 
that the entire circumferential surface of the PV ostium is adequately ablated.              
In contrast to the superior veins, the inferior PVs present particular challenges due to the 
angulation of the transseptal sheath in relation to the PV ostia. In general, advancement of the 
cryoballoon catheter into the left atrium results in a cranial movement of the catheter. For the 
inferior veins, this results in a non-central alignment of the cryoballoon catheter in relation to 
the PV axis, favouring contact along the superior margin of the PVs at the expense of 
suboptimal contact inferiorly. Similar to the other PVs, direct engagement should initially be 
attempted. Should optimal occlusion not be obtained through the above-mentioned torsional or 
angular manoeuvres, use of more sophisticated techniques may be required.[41] In patients 
with an early branching inferior PV, the "hockey stick" technique can be used to optimize 
tissue contact along the inferior PV circumference. After engaging the early branching inferior 
PV with the guidewire, a maximal bend is applied to the sheath in the superior-posterior LA. 
The sheath is then advanced, allowing the balloon to be propelled into the inferior part of the 
PV ostium. In patients with no or only a late branching inferior PV, the "pull-down" technique 
can be used to optimize tissue contact along the inferior PV circumference. With this 
technique, the balloon is positioned parallel to the PV ostium to ensure optimal contact along 
the superior circumference of the PV. Cryoablation is then initiated regardless of the presence 
of an inferior leak. After approximately 60-90 seconds, when full N2O flow into the inner 
balloon is reached and the cryoballoon has adhered to the endocardium, the balloon and sheath 
are gently withdrawn or pulled down in order to seal the inferior margin of the PV. Of note, 
this manoeuvre must be performed with great care due to the potential risk of severe vascular 
damage associated with the application of excessive force. Lastly, in the case of an inferior 
RIPV ostium with a large persistent inferior leak precluding an effective "pull-down", the "big 
loop" technique can be used. For this technique, the sheath is maximally bent. While directed 
towards the lateral posterior LA, the guidewire is advanced along the posterior mitral annulus 
until the RIPV is reached. Thereafter, the sheath is positioned to guide the balloon over the 
wire into the RIPV ostium.                                                                                     
Performing the Ablation Lesion and Intraprocedural Predictors of Success                 
When adequate circumferential contact is achieved, contrast material is flushed out of the 
catheter with saline, and a 240 second cryoablation is performed. Just prior to the onset of 
cryoablation, we apply gentle forward pressure on the cryoballoon catheter to maximise 
contact between the cryoballoon and PV antra.                                                
Although trough-freezing temperatures below -80ºC are theoretically obtainable, in practice it 
is rare to achieve a trough freezing temperature below -60 to -70ºC. Cryoballoon temperatures 
are generally lower in the superior PVs when compared with inferior PVs, most likely due to 
passive warming of the proximal thermocouple by blood flow from the superior PVs [42]. A 
minimal cryoballoon temperature at the end of freezing of <-51°C has been reported to predict 
PVI with 100% specificity for both superior and inferior PVs.  In contrast, temperatures at 120 
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seconds of ≥ -36°C for superior PVs and ≥ -33°C for inferior PVs predicted ineffective PVI 
with 95% specificity (PPV 80%) and a 97% specificity (PPV 82%) respectively. As such, we 
interrupt cryoablation lesions that do not attain trough temperatures below -35°C for inferior 
PVs and below -40°C for superior PVs at 120 sec.                                            
Similarly, whenever possible, we attempt to record real-time PV signals during ablation. A 
recent study by Dorwarth et al. demonstrated that sustained PVI was associated with a shorter 
mean time to conduction block (39 seconds) when compared to PVs with recovered PV 
conduction (125 seconds) [43]. The authors identified a cut-off time of 83 seconds for the 
prediction of stable sustained PVI without reconduction (86% sensitivity and 97% specificity). 
While this information is promising, we do not rely solely on this criterion to determine the 
utility (or lack thereof) for repeat lesions due to the lack of longer-term follow-up data. 
Moreover, in our experience with the Achieve catheter, real time recordings are obtainable in 
approximately 50% of PVs due to distal mapping catheter positioning (in order to achieve an 
adequate   cryoballoon   seal)   or  suboptimal   circumferential   mapping   catheter-vessel   wall 
contact.
Phrenic Nerve Monitoring                                                                                             
Prior to ablation of right-sided PVs, a standard 5-Fr quadripolar catheter is placed in the 
superior vena cava cranial to the right superior PV in order to pace the right phrenic nerve (10-
15 mA at 1.0-2.0 msec pulse width at a cycle length of 1000 msec). In addition to direct 
palpation   of   the   right   hemi-diaphragmatic   excursion,   it   is   our   practice   to   perform 
diaphragmatic electromyography (Figure 2). We immediately terminate cryoablation upon 
any perceived reduction in the strength of diaphragmatic contraction or a 30% reduction in the 
diaphragmatic CMAP amplitude.   Of note, if the procedure is performed under general 
anaesthesia, it is essential to discontinue use of paralytic agents at least 30 minutes prior to 
planned phrenic nerve pacing.
Confirmation of Isolation and the use of "Touch-ups"                                      
After ablation, as with all PVI procedures, we confirm the presence of PV entrance and exit 
block with a circular mapping catheter. In the rare instances when PVI was not achieved with 
the cryoballoon alone, we have targeted the few remaining left atrial–PV connections with the 
Freezor  Max 8-mm tip catheter  (Medtronic, Minneapolis, MN). Although some centers 
aggressively pursue multiple cryoballoon applications until PVI is achieved, we prefer focal 
ablation "touch-ups" for PVs that prove initially difficult to isolate. Arguments for limiting the 
number of cryoballoon applications included the potential increased risk of phrenic nerve injury 
during right-sided ablation, and prolonged procedural time in the left atrium; both of which must 
be balanced against the increased costs of additional ablation catheters. It should be noted that 
the efficacy of PVI has not been shown to differ amongst the two approaches (>98% of patients 
achieve complete PVI with either a cryoballoon-exclusive or "hybrid" cryoballoon-cryofocal 
approach).[11] As such, it remains a matter of physician preference.
Other   strategies   proposed   to   enhance   PVI   and   minimize   reconnection   include   serial 
cryoapplications based on the "freeze-thaw-freeze" principal. Alternatively, some authors have 
advocated for the performance of sequential engagement and cryoablation using multiple 
different PV branches in order to create sequential overlapping lesions.                                 
End   of   the   Procedure                                                              
At the end of the procedure, the presence of entrance block is reconfirmed in all PVs prior to 
removal of the transseptal sheath(s). While it has become standard practice to include a post-
procedure observation period to monitor for acute reconnection after RF ablation, our sense is 
that such a waiting period is not necessary after CBA. In contrast to the relatively high rate of 
procedural reconnection observed in studies of RF-based AF ablation (up to 50% in some 
series), the rate of acute reconnection post CBA appears to be low. In studies employing waiting 
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periods of up to 60 minutes, the pooled rate of acute recurrence among the 749 treated PVs was 
<1%   [40,43,46-48].   Moreover,   in   contrast   to   RF-based   ablation,   the   use   of   adjunctive 
pharmacologic agents such as adenosine and/or isoproterenol does not appear to provide 
additional   prognostic   information   in   patients   undergoing   CBA   [40,49,50].      
Figure 2:  Configuration of surface electrodes (A) and corresponding recordings (B) of the diaphragmatic 
compound motor action potential (CMAP) . Panel A depicts the surface electrode configuration used to record the 
diaphragmatic compound motor action potential (CMAP).  Electrodes are spaced 16 cm apart, one 5 cm above 
the xiphoid process and the second along the right costal margin.  Shown in Panel B are surface tracings from 
lead I and from the thoracic leads positioned to record diaphragmatic CMAPs.  The sweep speed is 100 mm/s.  
Note the stability of recorded CMAPs during right phrenic nerve pacing from the superior vena cava at 60 bpm. 
Reproduced with permission from Franceschi F, Dubuc M, Guerra PG, Khairy P. Phrenic nerve monitoring with 
diaphragmatic electromyography during cryoballoon ablation for atrial fibrillation: the first human application. 
Heart Rhythm. 2011;8(7):1068-1071. Copyright ©   Elsevier, 2011.                                                           
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Persistent   AF                                                                                          
 
While the acute success rate for paroxysmal AF is high (>98%), cryoballoon-based PVI alone 
for patients with persistent AF has been associated with high rates of arrhythmia recurrence 
(45% 1-year freedom from recurrent AF).[11] Unlike patients with paroxysmal AF, catheter 
ablation of persistent and permanent AF may require more extensive ablation beyond PVI 
[51,52]. In this patient population, the left atrial substrate plays a prominent role in AF 
maintenance.   Staged ablation strategies involving additional linear ablation and/or complex 
fractionated atrial electrogram-based (CFAE) ablation have yielded superior results [51,53]. 
Recently, a small hypothesis-generating study by Mansour et al. investigated an approach of 
cryoballoon PVI combined with conventional irrigated-RF based substrate modification in 22 
participants with persistent AF.[54] The authors explored the utility of a step-wise approach 
beginning with cryoballoon-based PVI (22 participants) followed by CFAE ablation in those 
who had persistent or inducible AF (19 participants). Thereafter, linear ablation of the roof, 
mitral isthmus, and septum was performed if ablation did not terminate AF or if the arrhythmia 
changed to an atrial tachycardia or flutter (10 participants). After a mean follow-up of 6 months, 
the single procedure freedom from recurrent AF off AAD was a remarkable 86%. Based upon 
these results, the authors concluded that a combined cryoballoon and RF approach is feasible 
with favourable short-term maintenance of sinus rhythm. Prospective studies are required to 
determine whether the safety and efficacy of a hybrid cryoballoon approach merits adoption in 
clinical   practice.                                                                        
Conclusion
Cryoballoon-based catheter ablation is a safe and effective technique for PVI with high acute 
and medium-term efficacy rates when used for paroxysmal AF. The rate of complications with 
CBA is relatively low, with the exception of a disproportionately increased incidence of phrenic 
nerve palsy (the majority of which are transient). Whether further benefits of cryoablation are 
realized will depend upon operator experience, refinements in the ablation technique, and 
evolutionary catheter development. Further studies, including direct comparison to conventional 
RF ablation are ongoing and will provide important insight into longer-term efficacy and safety.
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